semaglutide cardiovascular outcomes trial select glp 1 and in patients with obesity and prevalent heart failure: a prespecified analysis of the Semaglutide and Cardiovascular Outcomes in – Targeting the weight within: obesity

J.TraystmanR

Pattern 1: The Responder (approximately 60% of switchers) Achieves similar or better weight-loss velocity on Zepbound 7.5 to 10 mg compared to prior Wegovy 2.4 mg Tolerates titration well with transient nausea that resolves within 2 weeks per dose escalation Reaches maintenance dose by week 12 to 16 Reports subjective improvement in appetite suppression ("Zepbound feels stronger") This is the modal response

These medications also have different intended uses

To improve the safety and effectiveness of UC treatment, future research needs to better understand the pathogenic mechanisms related to the inflammatory response and intestinal epithelial barrier damage in the treatment and progression of UC disease